What is the difference between ARA-290 and HLDF-6?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing HLDF-6: Modulates cholinergic neurotransmission. Reduces amyloid-β toxicity and protects against oxidative stress-induced neuronal damage. May enhance memory consolidation via acetylcholine pathway upregulation.

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is HLDF-6 FDA approved?

HLDF-6 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is HLDF-6 administered in research settings?

In research settings, HLDF-6 is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs HLDF-6

Peptide Comparison

ARA-290 vs HLDF-6

Name: ARA-290 vs HLDF-6 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

HLDF-6

Human Leukemia Differentiation Factor 6

LongevityNot EvaluatedResearch Only

No providers listed yet

Full HLDF-6 profile →

Bottom line

ARA-290 has published research citations on file; HLDF-6 does not yet — the main evidence gap between them.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

HLDF-6

Half-life

—

Which One Should You Choose?

Your goal	Better option
Has published research citations	ARA-290
Further along in FDA review	ARA-290
More provider options (17 vs 0)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

HLDF-6

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

—

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

intranasal, subcutaneous

Availability

Research Only

Providers

17 listed

None listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

—

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

HLDF-6

No citations on file

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

HLDF-6

No citations on file.

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About HLDF-6

Modulates cholinergic neurotransmission. Reduces amyloid-β toxicity and protects against oxidative stress-induced neuronal damage. May enhance memory consolidation via acetylcholine pathway upregulation.

Research Areas

neuroprotectionmemory enhancementcognitive supportanti-aging

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

HLDF-6

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

HLDF-6

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

ARA-290

17 listed

Browse directory →

Providers offering

HLDF-6

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs HLDF-6 — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/ara-290/hldf-6

https://peptidebase.io/peptides/compare/ara-290/hldf-6 Methodology License Download JSON Download CSV